Rosetta Genomics, a leading medical research firm based in Israel, announced its newest cancer diagnostic test in a recent press release. The new form of diagnostic testing, known as microRNA testing, provides “advanced sensitivity and specificity relative to currently available tests.”
The microRNA test will be especially useful for physicians when making a pleural mesothelioma diagnosis, as it will be better equipped to distinguish between mesothelioma and other related diseases, including adenocarcinoma, a cancer of the glandular tissue. Additionally, the test will be less likely to yield a false result, giving physicians their patient's peace of mind.
Rosetta Genomics has recently purchased Parkway Clinical Laboratories, located in Bensalem, Pennsylvania, and will continue to develop their groundbreaking diagnostic testing methods here in the United States.
Pleural mesothelioma is a fatal form of cancer that attacks the pleural lining of the lungs. Presently, there is no known cure for mesothelioma, and the survival rate associated with this aggressive and painful cancer is less than one percent. Mesothelioma is caused by exposure to asbestos, and it can be decades after the initial exposure before an individual may begin to experience mesothelioma symptoms. Currently, physicians rely on x-rays, MRI scans and CT scans, as well as surgical biopsies, to determine whether or not an individual has pleural mesothelioma.
The Mesothelioma & Asbestos Awareness Center commends Rosetta Genomics for their continued dedication to advanced cancer diagnostic testing methods.
The Mesothelioma & Asbestos Awareness Center is the web’s leading resource for information related to asbestos exposure, mesothelioma, mesothelioma treatment methods, and more. For further information, please visit the Mesothelioma & Asbestos Awareness Center website.
